Alternative therapies in health and medicine · 2025
Specific Efficacy and Safety in the Clinical Application of Anlotinib for Thymic Carcinoma.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
He Jianbo, Liu Qianfei, Zeng Aiping, Ning Ruiling
Аннотация
BACKGROUND: Thymic carcinoma is a rare and aggressive malignancy characterized by high invasiveness, poor prognosis, and limited treatment options post-chemotherapy failure. Anlotinib, a novel tyrosine kinase inhibitor, has shown promise in inhibiting tumor growth and metastasis, suggesting potential as an adjunctive therapy in this challenging clinical setting.
OBJECTIVE: To evaluate the efficacy and safety of Anlotinib as a potential treatment option for thymic carcinoma post-chemotherapy failure, assessing its impact on tumor progression and patient survival outcomes.
CASE PRESENTATION: A 46-year-old female presented with a left supraclavicular mass persisting for one month. Percutaneous needle biopsy of the left mediastinal mass confirmed thymic carcinoma, specifically lowly differentiated squamous cell carcinoma.
MANAGEMENT: The patient underwent sequential treatment modalities, including first-line therapy, comprising four cycles of cisplatin + paclitaxel, followed by subsequent radiotherapy to the chest and neck. It was followed by second-line therapy involving six cycles of cyclophosphamide + pirarubicin + nedaplatin and third-line therapy consisting of four cycles of gemcitabine and nedaplatin. Notably, fourth-line therapy with Anlotinib monotherapy resulted in a progression-free survival of 10 months.
OUTCOME: Anlotinib emerges as a potential therapeutic option for thymic carcinoma post-chemotherapy failure. However, further validation through preclinical investigations and clinical trials is warranted.
CONCLUSION: Despite its limited ability to rapidly reduce tumor size, Anlotinib demonstrates efficacy in inhibiting neovascularization and impeding tumor progression and metastasis, thereby maintaining long-term tumor stability. It highlights its potential as a valuable adjunctive therapy in the management of thymic carcinoma.
KEYWORDS: thymic carcinoma, anti-angiogenic drugs, Anlotinib, progression-free survival, neovascularization inhibition, metastasis suppression.
OBJECTIVE: To evaluate the efficacy and safety of Anlotinib as a potential treatment option for thymic carcinoma post-chemotherapy failure, assessing its impact on tumor progression and patient survival outcomes.
CASE PRESENTATION: A 46-year-old female presented with a left supraclavicular mass persisting for one month. Percutaneous needle biopsy of the left mediastinal mass confirmed thymic carcinoma, specifically lowly differentiated squamous cell carcinoma.
MANAGEMENT: The patient underwent sequential treatment modalities, including first-line therapy, comprising four cycles of cisplatin + paclitaxel, followed by subsequent radiotherapy to the chest and neck. It was followed by second-line therapy involving six cycles of cyclophosphamide + pirarubicin + nedaplatin and third-line therapy consisting of four cycles of gemcitabine and nedaplatin. Notably, fourth-line therapy with Anlotinib monotherapy resulted in a progression-free survival of 10 months.
OUTCOME: Anlotinib emerges as a potential therapeutic option for thymic carcinoma post-chemotherapy failure. However, further validation through preclinical investigations and clinical trials is warranted.
CONCLUSION: Despite its limited ability to rapidly reduce tumor size, Anlotinib demonstrates efficacy in inhibiting neovascularization and impeding tumor progression and metastasis, thereby maintaining long-term tumor stability. It highlights its potential as a valuable adjunctive therapy in the management of thymic carcinoma.
KEYWORDS: thymic carcinoma, anti-angiogenic drugs, Anlotinib, progression-free survival, neovascularization inhibition, metastasis suppression.